Lung Academy podcast

ICI rechallenge now in the NSCLC ESMO guidelines: impact on clinical practice?

Prof. Em. Johan Vansteenkiste & Dr. Willemijn Theelen

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 20:27

In the fourth episode of the Lung Academy podcast series, Prof. Em. Johan Vansteenkiste, pulmonologist-oncologist at the University Hospital in Leuven, Belgium, and Dr. Willemijn Theelen, pulmonologist-oncologist at the Antoni van Leeuwenhoek Hospital in Amsterdam, the Netherlands, are invited to discuss the concept of Immune Checkpoint Inhibitors (ICI) rechallenge in the latest NSCLC ESMO guidelines and its impact on clinical practice. Both lung cancer experts provide further insights into the current gaps and the key questions that need to be answered before deciding to rechallenge. Finally, they also elaborate on which scientific hypotheses are currently being investigated in clinical trials.

Sanofi, MAT-BE-2300369, v1.0, 10/2023